The treatment of autoimmune blood diseases with antilymphocyte globulin.
Twelve patients with immunologically mediated diseases have been treated with ALG, alone or in combination. Tolerance was good. Indvidual case reports are discussed. Emphasis is placed on the duration of ALG-induced remissions, as well as on its favourable effect in humorally mediated autoimmune diseases. The absence of notable side effects, especially with the more recent and refined preparations, is stressed.
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013997:Time Factors
D000961:Antilymphocyte Serum; D003907:Dexamethasone; D003520:Cyclophosphamide